Hp β cyclodextrin

In vivo studies were performed in accordance with approved protocols from the Regional Ethical Review Board in Uppsala, Sweden. Briefly, 100,000 MB002 or MB-GTML cells were injected into cerebella (as described in ref. [14 (link)]) of 6–8-week-old female Athymic Nude-Foxn1nu mice (Harlan Laboratories). Seven days postinjection, mice were randomized into groups and administered JQ1 (50 mg/kg), Milciclib (10 mg/kg), JQ1 together with Milciclib (50 mg/kg and 10 mg/kg, respectively) or vehicle alone (DMSO) in 10% HP-β-Cyclodextrin (Sigma) on alternating days via intraperitoneal injection for 14 days. Cisplatin 2 mg/kg (Sigma) in DMSO:10% HP-β-Cyclodextrin was administered weekly four times. Statistical analysis of Kaplan–Meier survival curves was performed using the log-rank (Mantel–Cox) test.

Ctdnep1-deficient Tumors cells were subcutaneously injected into eight-week-old female athymic BALB/c nude mice or NSG mice. Tumors will be harvested after 6–10 weeks and quantified. 1 × 10⁵ NPCs in a 5 μl with 2 μl matrigel were stereotactically injected into the NSG mouse cerebellum. Animals were monitored weekly and euthanized when they showed signs of brain tumor. The mouse brain tissue with tumor was embedded in paraffin and sectioned at a thickness of 5 μm for H/E and immunohistochemistry assays. Ctdnep1 cKO tumors exhibit the large cell/anaplastic morphology observed in MYC-driven Group 3 MB, which was confirmed by a neuropathologist Dr. Christina Fuller. The NSG mice with Ctdnep1-cKO NPC tumors in the cerebellum were randomized into different groups and administered Prexasertib (15 mg/kg) and/or JQ1 (50 mg/kg) or vehicle (10% DMSO in 10% HP-β-Cyclodextrin, Sigma) on alternating days via intraperitoneal injection for 14 days^{64 (link)}.